NovaBay Pharmaceuticals (NBY) Operating Income (2016 - 2025)
Historic Operating Income for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.
- NovaBay Pharmaceuticals' Operating Income rose 2624.78% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 million, marking a year-over-year increase of 3161.29%. This contributed to the annual value of -$5.8 million for FY2024, which is 4234.52% down from last year.
- According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Operating Income is -$1.3 million, which was up 2624.78% from -$228000.0 recorded in Q4 2024.
- Over the past 5 years, NovaBay Pharmaceuticals' Operating Income peaked at -$228000.0 during Q4 2024, and registered a low of -$9.4 million during Q4 2022.
- In the last 5 years, NovaBay Pharmaceuticals' Operating Income had a median value of -$1.5 million in 2021 and averaged -$2.0 million.
- Per our database at Business Quant, NovaBay Pharmaceuticals' Operating Income crashed by 19511.58% in 2022 and then soared by 8930.62% in 2023.
- Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Operating Income stood at -$3.2 million in 2021, then tumbled by 195.12% to -$9.4 million in 2022, then skyrocketed by 89.31% to -$1.0 million in 2023, then soared by 77.38% to -$228000.0 in 2024, then plummeted by 450.88% to -$1.3 million in 2025.
- Its Operating Income was -$1.3 million in Q3 2025, compared to -$228000.0 in Q4 2024 and -$1.7 million in Q3 2024.